Switching between antitumour necrosis factor alpha biologic agents - is patient weight an important consideration?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2009-05, Vol.160 (5), p.1123-1124
1. Verfasser:	Downs, A.M.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	adalimumab Antibodies, Monoclonal - administration & dosage Biological and medical sciences Body Mass Index Body Weight Dermatologic Agents - administration & dosage Dermatology Etanercept Female Humans Immunoglobulin G - administration & dosage Infliximab Male Medical sciences psoriasis Psoriasis - drug therapy Receptors, Tumor Necrosis Factor - administration & dosage switching Treatment Failure Tumor Necrosis Factor-alpha
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!